Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Merck, Daiichi Sankyo withdraw US application for lung cancer therapy - Regional Media News

Sept 25 (Reuters) - Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the companies said on Friday. The decision followed discussions with the US Food and Drug Administration, which determined that the data from [...]

Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Sept 25 (Reuters) - Merck ​and ‌Daiichi Sankyo ‌have ​voluntarily ⁠withdrawn ⁠their US application ​seeking ⁠accelerated ⁠approval for ​their ​experimental lung cancer ‌therapy, ⁠the drugmakers said ⁠on ‌Friday. (Reporting ⁠by ​Kamal ‌Choudhury in ​Be...

Merck, Daiichi withdraw ifinatamab FDA application

Merck and Daiichi Sankyo withdrew the ifinatamab BLA on Sept. 25 after FDA discussions; the Oct. 10 action date had been set.

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn